ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2021
The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Lateral Flow Assay to detect CXCL10 as a diagnose-supporting biomarker for Polyomavirus-associated Nephropathy (PVAN) after kidney transplantation (KTx).Scientific reports · 2026Article
- Interferon-Inducible Gene Upregulation Correlates With Successful Viral Clearance in Patients With BK Polyomavirus-Associated Nephropathy.Kidney international reports · 2026Article
- Benchmarking urinary cell transcriptomes for noninvasive differentiation of BK polyomavirus-associated nephropathy from T cell-mediated rejection.JCI insight · 2026Article
- Article
- Urinary Basigin/CD147 is a useful marker of acute T cell-mediated rejection in kidney transplant recipients.Renal failure · 2025Article
- Updates in the Diagnosis and Treatment of BK Viraemia in Kidney Transplant Recipients: Current and Future Insights.Journal of clinical medicine · 2025Review
- BK Polyomavirus-associated nephropathy - diagnostic and treatment standard.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Diagnosing Polyomavirus Nephropathy Without a Biopsy: Validation of the Urinary Polyomavirus-Haufen Test in a Proof-of-Concept Study Including Uromodulin Knockout Mice.The Journal of infectious diseases · 2024Article
- Peritubular and Tubulointerstitial Inflammation as Predictors of Impaired Viral Clearance in Polyomavirus Nephropathy.Journal of clinical medicine · 2024Article
- Shedding Light on Viral Shedding: Novel Insights into Nuclear Assembly, Cytoplasmic Transformation and Extracellular Vesicle Release of the BK Virus.International journal of molecular sciences · 2024Article
- Polyomavirus nephropathy: diagnosis, histologic features, and differentiation from acute rejection.Clinical transplantation and research · 2024Review
- Polyomavirus Nephropathy in ABO Blood Group-Incompatible Kidney Transplantation: Torque Teno Virus and Immunosuppressive Burden as an Approximation to the Problem.Kidney international reports · 2024Article
- Acute Kidney Injury and BK Polyomavirus in Urine Sediment Cells.International journal of molecular sciences · 2023Article
- Article
- A case of acute kidney injury due to native kidney BK polyomavirus-associated nephropathy in a human T-lymphotropic virus type 1 carrier.BMC nephrology · 2023Article
- Lessons from Polyomavirus Immunofluorescence Staining of Urinary Decoy Cells.Life (Basel, Switzerland) · 2023Article
- Pathological Approach to Kidney Allograft Infection.Biomedicines · 2023Review
- A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM.Life science alliance · 2023Article
- Characteristics, risk factors and outcome of BKV nephropathy in kidney transplant recipients: a case-control study.BMC infectious diseases · 2023Article
- Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Polyomavirus nephropathy (PVN) remained inadequately classified until 2018 when the Banff Working Group published a new 3-tier morphologic classification scheme derived from in-depth statistical analysis of a large multinational patient cohort. Here we report a multicenter "modern-era" validation study that included 99 patients with definitive PVN transplanted post January 1, 2009 and followed the original 2018 study design. Results validate the PVN classification, that is, the 3 PVN disease classes predicted clinical presentation, allograft function, and outcome independent of therapeutic intervention. PVN class 1 compared to classes 2 and 3 was diagnosed earlier (16.9 weeks posttransplant [median], P = .004), and showed significantly better function at 24 months postindex biopsy (serum creatinine 1.75 mg/dl, geometric mean, vs class 2: P = .037, vs class 3: P = .013). Class 1 presented during long-term follow-up with a low graft failure rate: 5% class 1, vs 30% class 2, vs 50% class 3 (P = .009). Persistent PVN was associated with an increased risk for graft failure (and functional decline in class 2 at 24 months postdiagnosis; serum creatinine with persistence: 2.48 mg/dL vs 1.65 with clearance, geometric means, P = .018). In conclusion, we validate the 2018 Banff Working Group PVN classification that provides significant clinical information and enhances comparative data analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.